BeOne Medicines Ltd. (ONC) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Medical - Pharmaceuticals उद्योग. वर्तमान CEO हैं John V. Oyler.
ONC के पास है IPO तिथि 2016-02-02, 11,000 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Market, बाजार पूंजीकरण $33.13B.
BeOne Medicines is a global oncology company dedicated to discovering, developing, and commercializing innovative cancer therapies. Originally founded as BeiGene in 2010, the company rebranded to BeOne in late 2024 and relocated its headquarters to Basel, Switzerland in 2025, now operating across over 45 countries. The company has established market leadership in immuno-oncology and targeted therapies, with flagship products including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications worldwide, and Brukinsa (zanubrutinib), a BTK inhibitor that generates over $1.3 billion in annual sales across the U.S., Europe, and China. BeOne's strategy combines internal research and development with externally sourced assets to build a robust pipeline targeting hematologic malignancies and solid tumors.
